Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy
We aimed to identify the clinical characteristics and examine outcomes in patients with significant tricuspid regurgitation (TR) who received transcatheter tricuspid valve intervention (TTVI) compared with guideline directed medical therapy (GDMT). Between 2015 and 2019, 124 patients with symptomati...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2020-12, Vol.320, p.49-54 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | |
| container_start_page | 49 |
| container_title | International journal of cardiology |
| container_volume | 320 |
| creator | Cai, Sean Bowers, Nicolas Dhoot, Arjan Ho, Edwin C. Ong, Geraldine Eckstein, Janine Edwards, Jeremy Fam, Neil Connelly, Kim A. |
| description | We aimed to identify the clinical characteristics and examine outcomes in patients with significant tricuspid regurgitation (TR) who received transcatheter tricuspid valve intervention (TTVI) compared with guideline directed medical therapy (GDMT).
Between 2015 and 2019, 124 patients with symptomatic severe TR were assessed at St. Michael's Hospital. Seventy-one patients were ineligible and received GDMT only while 53 patients received TTVI and GDMT. During follow-up, TTVI was associated with significant improvements in NYHA functional class and 6-min walk distance (p |
| doi_str_mv | 10.1016/j.ijcard.2020.07.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2425593542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527320334665</els_id><sourcerecordid>2425593542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-dca89117983460082c682ec0b0552afabd81bd9ee92f8154cf9b2d8d2bf4fb243</originalsourceid><addsrcrecordid>eNp9kcFu3CAURVHVqJmm_YOqYtmNXcDYhi4qVVHbRIqaTbJGGB4JI49xAVuaP8hnh5GTLrtCoHN4uu8i9ImSmhLafd3Xfm90tDUjjNSkrwkVb9COip5XtG_5W7QrWF-1rG_O0fuU9oQQLqV4h84b1gkmO7ZDT390XqIe8aNPOcQjDg4nWCECztGbJc3e4ggPS3zwWWcfpm_4dskmHCBh7TLEwukpGZ0fYbu9WqseV8B-Kq8rTCcVF23WESzOAR_AelMGFy_q-fgBnTk9Jvj4cl6g-18_7y6vqpvb39eXP24q03QsV9ZoISntpWh4R4hgpiQBQwbStkw7PVhBBysBJHOCttw4OTArLBscdwPjzQX6sv07x_B3gZTVwScD46gnCEtSjLO2lU3LWUH5hpoYUorg1Bz9QcejokSdOlB7tXWgTh0o0qvSQdE-v0xYhhLyn_S69AJ83wAoOVcPUSXjYTJlIRFMVjb4_094Bi2hnl8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425593542</pqid></control><display><type>article</type><title>Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cai, Sean ; Bowers, Nicolas ; Dhoot, Arjan ; Ho, Edwin C. ; Ong, Geraldine ; Eckstein, Janine ; Edwards, Jeremy ; Fam, Neil ; Connelly, Kim A.</creator><creatorcontrib>Cai, Sean ; Bowers, Nicolas ; Dhoot, Arjan ; Ho, Edwin C. ; Ong, Geraldine ; Eckstein, Janine ; Edwards, Jeremy ; Fam, Neil ; Connelly, Kim A.</creatorcontrib><description>We aimed to identify the clinical characteristics and examine outcomes in patients with significant tricuspid regurgitation (TR) who received transcatheter tricuspid valve intervention (TTVI) compared with guideline directed medical therapy (GDMT).
Between 2015 and 2019, 124 patients with symptomatic severe TR were assessed at St. Michael's Hospital. Seventy-one patients were ineligible and received GDMT only while 53 patients received TTVI and GDMT. During follow-up, TTVI was associated with significant improvements in NYHA functional class and 6-min walk distance (p < .001). GDMT patients had lower survival (46.9% vs 75.1%, p = .047) and lower freedom from heart failure hospitalization (HHF) and mortality (33.2% vs 62.7%, p = .027), higher incidences per 100 person-year of gastrointestinal bleeding [15.58 (95% CI 8.90–25.31) vs 4.24 (95% CI 0.85–12.37), p = .04] and acute kidney injury [36.98 (95% CI 26.17–50.76) vs 14.12 (95% CI 6.76–25.96), p = .001] compared with TTVI patients.
TTVI in addition to GDMT was effective at improving TR symptoms, functional status, and was associated with lower rates of all-cause mortality, the combined endpoint of HHF and mortality, AKI and GI bleeding. Future randomized controlled trials on TTVI are needed.
•Severe tricuspid regurgitation (TR) is associated with significant morbidity and mortality.•Transcathether tricuspid valve intervention (TTVI) may reduce severity of TR.•TTVI may improve functional capacity and symptom burden.•TTVI may reduce hospitalization for heart failure and mortality.•TTVI may reduce incidence of renal injury and gastrointestinal bleed.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2020.07.018</identifier><identifier>PMID: 32682962</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cardiac Catheterization ; Heart failure ; Heart Valve Prosthesis Implantation ; Humans ; Treatment Outcome ; Tricuspid regurgitation ; Tricuspid Valve - diagnostic imaging ; Tricuspid Valve - surgery ; Tricuspid Valve Insufficiency - diagnostic imaging ; Tricuspid Valve Insufficiency - surgery ; TTVI</subject><ispartof>International journal of cardiology, 2020-12, Vol.320, p.49-54</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-dca89117983460082c682ec0b0552afabd81bd9ee92f8154cf9b2d8d2bf4fb243</citedby><cites>FETCH-LOGICAL-c362t-dca89117983460082c682ec0b0552afabd81bd9ee92f8154cf9b2d8d2bf4fb243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167527320334665$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32682962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Sean</creatorcontrib><creatorcontrib>Bowers, Nicolas</creatorcontrib><creatorcontrib>Dhoot, Arjan</creatorcontrib><creatorcontrib>Ho, Edwin C.</creatorcontrib><creatorcontrib>Ong, Geraldine</creatorcontrib><creatorcontrib>Eckstein, Janine</creatorcontrib><creatorcontrib>Edwards, Jeremy</creatorcontrib><creatorcontrib>Fam, Neil</creatorcontrib><creatorcontrib>Connelly, Kim A.</creatorcontrib><title>Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>We aimed to identify the clinical characteristics and examine outcomes in patients with significant tricuspid regurgitation (TR) who received transcatheter tricuspid valve intervention (TTVI) compared with guideline directed medical therapy (GDMT).
Between 2015 and 2019, 124 patients with symptomatic severe TR were assessed at St. Michael's Hospital. Seventy-one patients were ineligible and received GDMT only while 53 patients received TTVI and GDMT. During follow-up, TTVI was associated with significant improvements in NYHA functional class and 6-min walk distance (p < .001). GDMT patients had lower survival (46.9% vs 75.1%, p = .047) and lower freedom from heart failure hospitalization (HHF) and mortality (33.2% vs 62.7%, p = .027), higher incidences per 100 person-year of gastrointestinal bleeding [15.58 (95% CI 8.90–25.31) vs 4.24 (95% CI 0.85–12.37), p = .04] and acute kidney injury [36.98 (95% CI 26.17–50.76) vs 14.12 (95% CI 6.76–25.96), p = .001] compared with TTVI patients.
TTVI in addition to GDMT was effective at improving TR symptoms, functional status, and was associated with lower rates of all-cause mortality, the combined endpoint of HHF and mortality, AKI and GI bleeding. Future randomized controlled trials on TTVI are needed.
•Severe tricuspid regurgitation (TR) is associated with significant morbidity and mortality.•Transcathether tricuspid valve intervention (TTVI) may reduce severity of TR.•TTVI may improve functional capacity and symptom burden.•TTVI may reduce hospitalization for heart failure and mortality.•TTVI may reduce incidence of renal injury and gastrointestinal bleed.</description><subject>Cardiac Catheterization</subject><subject>Heart failure</subject><subject>Heart Valve Prosthesis Implantation</subject><subject>Humans</subject><subject>Treatment Outcome</subject><subject>Tricuspid regurgitation</subject><subject>Tricuspid Valve - diagnostic imaging</subject><subject>Tricuspid Valve - surgery</subject><subject>Tricuspid Valve Insufficiency - diagnostic imaging</subject><subject>Tricuspid Valve Insufficiency - surgery</subject><subject>TTVI</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu3CAURVHVqJmm_YOqYtmNXcDYhi4qVVHbRIqaTbJGGB4JI49xAVuaP8hnh5GTLrtCoHN4uu8i9ImSmhLafd3Xfm90tDUjjNSkrwkVb9COip5XtG_5W7QrWF-1rG_O0fuU9oQQLqV4h84b1gkmO7ZDT390XqIe8aNPOcQjDg4nWCECztGbJc3e4ggPS3zwWWcfpm_4dskmHCBh7TLEwukpGZ0fYbu9WqseV8B-Kq8rTCcVF23WESzOAR_AelMGFy_q-fgBnTk9Jvj4cl6g-18_7y6vqpvb39eXP24q03QsV9ZoISntpWh4R4hgpiQBQwbStkw7PVhBBysBJHOCttw4OTArLBscdwPjzQX6sv07x_B3gZTVwScD46gnCEtSjLO2lU3LWUH5hpoYUorg1Bz9QcejokSdOlB7tXWgTh0o0qvSQdE-v0xYhhLyn_S69AJ83wAoOVcPUSXjYTJlIRFMVjb4_094Bi2hnl8</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Cai, Sean</creator><creator>Bowers, Nicolas</creator><creator>Dhoot, Arjan</creator><creator>Ho, Edwin C.</creator><creator>Ong, Geraldine</creator><creator>Eckstein, Janine</creator><creator>Edwards, Jeremy</creator><creator>Fam, Neil</creator><creator>Connelly, Kim A.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy</title><author>Cai, Sean ; Bowers, Nicolas ; Dhoot, Arjan ; Ho, Edwin C. ; Ong, Geraldine ; Eckstein, Janine ; Edwards, Jeremy ; Fam, Neil ; Connelly, Kim A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-dca89117983460082c682ec0b0552afabd81bd9ee92f8154cf9b2d8d2bf4fb243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cardiac Catheterization</topic><topic>Heart failure</topic><topic>Heart Valve Prosthesis Implantation</topic><topic>Humans</topic><topic>Treatment Outcome</topic><topic>Tricuspid regurgitation</topic><topic>Tricuspid Valve - diagnostic imaging</topic><topic>Tricuspid Valve - surgery</topic><topic>Tricuspid Valve Insufficiency - diagnostic imaging</topic><topic>Tricuspid Valve Insufficiency - surgery</topic><topic>TTVI</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cai, Sean</creatorcontrib><creatorcontrib>Bowers, Nicolas</creatorcontrib><creatorcontrib>Dhoot, Arjan</creatorcontrib><creatorcontrib>Ho, Edwin C.</creatorcontrib><creatorcontrib>Ong, Geraldine</creatorcontrib><creatorcontrib>Eckstein, Janine</creatorcontrib><creatorcontrib>Edwards, Jeremy</creatorcontrib><creatorcontrib>Fam, Neil</creatorcontrib><creatorcontrib>Connelly, Kim A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Sean</au><au>Bowers, Nicolas</au><au>Dhoot, Arjan</au><au>Ho, Edwin C.</au><au>Ong, Geraldine</au><au>Eckstein, Janine</au><au>Edwards, Jeremy</au><au>Fam, Neil</au><au>Connelly, Kim A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>320</volume><spage>49</spage><epage>54</epage><pages>49-54</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>We aimed to identify the clinical characteristics and examine outcomes in patients with significant tricuspid regurgitation (TR) who received transcatheter tricuspid valve intervention (TTVI) compared with guideline directed medical therapy (GDMT).
Between 2015 and 2019, 124 patients with symptomatic severe TR were assessed at St. Michael's Hospital. Seventy-one patients were ineligible and received GDMT only while 53 patients received TTVI and GDMT. During follow-up, TTVI was associated with significant improvements in NYHA functional class and 6-min walk distance (p < .001). GDMT patients had lower survival (46.9% vs 75.1%, p = .047) and lower freedom from heart failure hospitalization (HHF) and mortality (33.2% vs 62.7%, p = .027), higher incidences per 100 person-year of gastrointestinal bleeding [15.58 (95% CI 8.90–25.31) vs 4.24 (95% CI 0.85–12.37), p = .04] and acute kidney injury [36.98 (95% CI 26.17–50.76) vs 14.12 (95% CI 6.76–25.96), p = .001] compared with TTVI patients.
TTVI in addition to GDMT was effective at improving TR symptoms, functional status, and was associated with lower rates of all-cause mortality, the combined endpoint of HHF and mortality, AKI and GI bleeding. Future randomized controlled trials on TTVI are needed.
•Severe tricuspid regurgitation (TR) is associated with significant morbidity and mortality.•Transcathether tricuspid valve intervention (TTVI) may reduce severity of TR.•TTVI may improve functional capacity and symptom burden.•TTVI may reduce hospitalization for heart failure and mortality.•TTVI may reduce incidence of renal injury and gastrointestinal bleed.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32682962</pmid><doi>10.1016/j.ijcard.2020.07.018</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2020-12, Vol.320, p.49-54 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2425593542 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Cardiac Catheterization Heart failure Heart Valve Prosthesis Implantation Humans Treatment Outcome Tricuspid regurgitation Tricuspid Valve - diagnostic imaging Tricuspid Valve - surgery Tricuspid Valve Insufficiency - diagnostic imaging Tricuspid Valve Insufficiency - surgery TTVI |
| title | Natural history of severe tricuspid regurgitation: Outcomes after transcatheter tricuspid valve intervention compared to medical therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T06%3A27%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20history%20of%20severe%20tricuspid%20regurgitation:%20Outcomes%20after%20transcatheter%20tricuspid%20valve%20intervention%20compared%20to%20medical%20therapy&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Cai,%20Sean&rft.date=2020-12-01&rft.volume=320&rft.spage=49&rft.epage=54&rft.pages=49-54&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2020.07.018&rft_dat=%3Cproquest_cross%3E2425593542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425593542&rft_id=info:pmid/32682962&rft_els_id=S0167527320334665&rfr_iscdi=true |